OM Stock: TD Cowen Maintains Buy Rating, May 2026

TD Cowen maintained its Buy rating on Outset Medical (OM) but lowered its price target to $10 from $12 on May 8, 2026. The analyst action reflects near-term challenges facing the medical device maker. OM stock trades at $3.70, down sharply from its 52-week high of $21.98. Despite the price target cut, Cowen’s OM stock rating remains constructive. The company develops the Tablo Hemodialysis System for dialysis care. Meyka AI rates OM with a grade of B, suggesting a hold position for investors.

TD Cowen Maintains Buy Rating on OM Stock

Analyst Action and Price Target Adjustment

TD Cowen kept its Buy rating on Outset Medical intact while reducing the price target to $10 from $12. This adjustment signals caution about near-term execution despite long-term confidence. The OM stock rating reflects belief in the company’s hemodialysis technology but acknowledges current market pressures. At $3.70 per share, the stock trades well below the new target, suggesting potential upside. The analyst maintains conviction in the business model even as it navigates operational headwinds.

Market Context and Stock Performance

Outset Medical’s stock has faced significant pressure, declining 21% in one day and 77% over the past year. The company’s market cap stands at $68.5 million, reflecting investor concerns about profitability. OM trades at a 0.62 price-to-book ratio, indicating the market values it below tangible assets. The stock’s RSI of 38 suggests oversold conditions. Despite these challenges, the OM stock rating from Cowen remains positive, betting on eventual recovery.

Financial Metrics and Operational Challenges

Profitability and Cash Flow Concerns

Outset Medical faces significant profitability headwinds with a negative net margin of 63.7% and negative ROE of 55.9%. The company burns cash, with negative free cash flow per share of $1.86. Operating losses continue to pressure the balance sheet. However, the company maintains a strong current ratio of 6.3, providing liquidity cushion. Cash per share stands at $8.53, offering runway for operations. These metrics explain why TD Cowen lowered the price target, though the OM stock rating remains constructive.

Revenue and Growth Trajectory

Outset Medical generated $6.40 in revenue per share trailing twelve months. Revenue growth reached 5.1% year-over-year, modest but positive. Gross margins improved to 40.6%, showing the core business generates profit before operating expenses. The company’s inventory turnover of 1.4 suggests slow product movement. Days inventory outstanding of 260 days indicates working capital challenges. Despite these operational metrics, the OM stock rating reflects confidence in the Tablo system’s market adoption potential.

Analyst Consensus and Meyka AI Grade

Broader Analyst Coverage

Outset Medical has mixed analyst support with 3 Buy ratings and 2 Hold ratings among tracked analysts. The consensus leans bullish, though not unanimously. Meyka AI rates OM with a B grade, factoring in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. This grade suggests the stock offers moderate opportunity despite current challenges. The OM stock rating landscape shows divided opinion on near-term direction. Cowen’s maintained Buy stance aligns with the bullish minority view.

Valuation and Price Targets

The new $10 price target from TD Cowen implies 170% upside from current levels. This aggressive target reflects belief in long-term value creation. The stock trades at 0.58 price-to-sales, relatively cheap for a medical device company. However, negative earnings make traditional valuation metrics difficult. The OM stock rating depends heavily on execution in the dialysis market. Cowen’s target assumes successful commercialization of the Tablo system and path to profitability.

Technical Indicators and Market Sentiment

Oversold Conditions and Momentum

Technical analysis shows RSI of 38.4, indicating oversold conditions that often precede bounces. The CCI of -231 confirms extreme oversold status. Williams %R at -90.16 suggests maximum selling pressure. However, the ADX of 26.3 shows a strong downtrend remains in place. These mixed signals suggest caution despite oversold readings. The OM stock rating from technicians would be cautious until trend reversal confirms. Volume remains elevated at 383,663 shares, double the average, showing active selling.

Forecast and Long-Term Outlook

Meyka AI forecasts OM stock reaching $12.79 within one year and $28.05 within five years. These projections assume successful execution and market adoption. The monthly forecast of $3.35 suggests near-term consolidation. The OM stock rating incorporates these forecasts into its B grade assessment. Long-term investors betting on the Tablo system’s success may find current prices attractive. However, near-term volatility and profitability challenges warrant careful position sizing.

Final Thoughts

TD Cowen maintains a Buy rating on Outset Medical with a $10 price target, offering significant upside from current $3.70 levels despite execution risks. Analyst sentiment is cautiously optimistic with 3 Buy and 2 Hold ratings. Meyka AI’s B grade suggests holding. The company’s strong balance sheet and revenue growth provide recovery potential, but negative margins and cash burn warrant monitoring. Investors should track quarterly results and Tablo system adoption closely before making investment decisions.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.